Pharmaceuticals

FDA approves Filspari for adult patients with IgA nephropathy

bexib
By bexib 0 Min Read

Filspari is believed to be the first non-immunosuppressant treatment to significantly slow the decline of kidney function in adults with IgA nephropathy.

You Might Also Like

Braeburn Discusses BRIXADI® Study and Fentanyl’s Impact on OUD

Transforming a biotech incubator into a commercial enterprise

COA Validation: A Critical Step for Accurate and Reliable Clinical Trial Data

FDA approves Breyanzi for relapsed or refractory mantle cell lymphoma

ICL receives £10 million donation to advance heart and lung research

Share This Article
Previous Article Russia’s Prosecution of the War in Ukraine: Can It Square the Circle of Probable Boundary Conditions?
Next Article First survey of regional housing markets in August
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Hotel chef obtains new qualification
Hospitality & Tourism
Print the shirt with 3D James Nobak
Manufacturing
IHG Hotels & Resorts Announces Public Space Design of Innovative Experience Holiday Inn Express
Hospitality & Tourism
Flashback: Magnetic Stripe Reader – Manufacturer:
Manufacturing